Related Experiment Video
Updated: Nov 2, 2025
07:09
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
2.1K
Towards precision medicine in heart failure.
Chad S Weldy1,2, Euan A Ashley3,4
1Department of Medicine, Division of Cardiology, Stanford University, Palo Alto, CA, USA.
Nature Reviews. Cardiology
|June 10, 2021
Summary
New heart failure (HF) therapies are emerging, driven by genetic insights and precision medicine. This review bridges HF biology, genetics, and advanced treatments for personalized patient care.
Area of Science:
- Cardiology and Genetics
- Molecular Biology and Pharmacology
Background:
- The past decade has seen a near doubling of therapies for heart failure (HF) with reduced ejection fraction.
- Emerging treatments target HF caused by hypertrophic and infiltrative diseases, signaling a new era in cardiovascular medicine.
Purpose of the Study:
- To review the biology of HF, linking genetic factors to structural remodeling and therapeutic mechanisms.
- To highlight advances in understanding both Mendelian and complex genetics of HF.
- To explore machine learning applications for HF subcategorization and personalized prescribing.
Main Methods:
- Review of current literature on HF biology, genetics, and therapeutics.
- Analysis of causal relationships between genetic predispositions and HF outcomes.
- Discussion of novel therapeutic mechanisms and machine learning applications in HF.
Main Results:
- Significant advancements in HF therapies and understanding of its genetic underpinnings.
- Integration of biological insights with genetic predispositions for precision medicine approaches.
- Potential for machine learning to refine HF subtyping and guide treatment selection.
Conclusions:
- A new era of precision medicine in HF is emerging, integrating genetic insights with therapeutic strategies.
- Bridging the gap between HF pathophysiology, clinical presentation, and treatment options is crucial.
- A roadmap for the future of precision medicine in HF is presented, emphasizing personalized approaches.
Related Concept Videos
01:30Heart Failure V: Medical Management
60
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
60
01:29Cardiomyopathy V: Interprofessional Care
93
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
93
01:30Cardiomyopathy II: Dilated Cardiomyopathy
111
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
111
01:22Heart Failure VI: Adjunct Therapies
69
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
69
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
109
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
109
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
635
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
635